sunitinib

Sunitinib is an orally administered small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor developed for the treatment of various cancers. It inhibits cellular signaling by targeting multiple RTKs, including platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor type 1 (CSF-1R), and glial cell-line derived neurotrophic factor receptor (RET). By blocking these kinases, sunitinib interferes with tumor growth, pathologic angiogenesis, and metastatic progression. Sunitinib is primarily indicated for advanced renal cell carcinoma (RCC), imatinib-resistant gastrointestinal stromal tumor (GIST), adjuvant treatment of RCC at high risk of recurrence following nephrectomy, and progressive well-differentiated pancreatic neuroendocrine tumors in adults with unresectable locally advanced or metastatic disease[5][7][8].

Brand names

Sutent

Other names

sunitinib malate